go 대다모픽 1위 블랙포레 루트파워

제가 제일 먼저 적는 것 같습니다.

  • 24년 전

  • 1,675
0
별이야기는 없고... 그냥 두타에 관한 이야기가 올라 와 있길레 여기 퍼 놓습니다..

물론 좀 있으면, 대다모에서 번역을 해 놓겠지만,

그냥 여기에다 옮겨놓고 싶네요.. (요즘 맘이 많이 답답해서)

이해해 주십시요...

그리고 이렇게 hairlosshelp가 취재해 놓은 것을 보면, 올 하반기에는 정말 두타가 나오려나 봅니다.


New Dutasteride Study and Latest Update
April 04, 2002 - Hairlosshelp.com spoke to a representative at Glaxo and were were informed that they are in fact waiting for the approval of the sNDA before marketing the drug. They expect to release the drug sometime in the latter half of 2002.

The following study was presented by Glaxo at the recent 17th Annual Congress of the European Association of Urology (EAU) in Birmingham, England.



The Impact Of Dutasteride, a Novel 5-a- Reductase Inhibitor, on the Hallmarks of BPH Progression and Outcomes
Boyle Peter1 , Roehrborn Claus2, Andriole Gerald3, Nickel J Curtis4, Hofner, Klaus5 , O'Leary, Michael 6

1Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy, 2 The University of Texas Southwestern Medical Center, Dallas, TX, USA; 3Division of Urology, Washington University School of Medicine, St. Louis, MO, USA; 4Department of Urology, Queen's University, Kingston, Ontario, Canada; 5 Urology Clinic, Oberhausen, Germany, 6Harvard Medical School, Boston, USA.

INTRODUCTION & OBJECTIVES: Benign Prostatic Hyperplasia (BPH) is a progressive condition characterised by increasing deterioration of symptoms, decreased urinary flow, increased prostate volume (PV) as well as increased risk of acute urinary retention (AUR) and BPH-related surgery. The objective of these clinical studies was to demonstrate the impact of dutasteride, a novel dual 5 ?-reductase inhibitor on the hallmarks of BPH progression and outcomes.

MATERIALS & METHODS: Three 2-year multi-center, double-blind, placebo-controlled studies on dutasteride were conducted (n = 4325 total). A 1-month placebo run-in period was followed by randomisation to active treatment with dutasteride, 0.5 mg/day, or placebo. Inclusion criteria were: moderate to severe symptoms (AUA-SI ³ 12), prostate volume ³ 30 cc; prostate-specific antigen ³ 1.5 ng/ml and £ 10.0ng/ml; and maximum flow rate (Qmax) £ 15 ml/sec. Symptoms were assessed by the American Urological Association Symptom Index Questionnaire (AUA-SI). BPH-specific health status and Qmax were assessed at baseline and at 1, 3, 6, 12,18 and 24 months. BPH-specific health status was measured using BPH Impact Index (BII). Prostate volume (PV) was measured at screening (visit 1), 1 (one study), 3 (one study) 6, 12 and 24 months. Statistical analyses were performed using two-sided tests of significance at alpha = 0.05; At Visit results were analysed.

RESULTS: Dutasteride significantly improved symptoms as early as 3 months in one study (-2.6 vs. -1.9 adjusted mean score change from baseline for dutasteride vs. placebo groups [p = 0.016]) and at 6 months in the pooled analysis of the three studies (-3.2 vs.-2.5 [p < 0.001]) with sustained improvement up to 24 months (-4.5 vs. -2.3 [p < 0.001]). Qmax was improved from 1 month in a pooled analysis of the three studies and by 3 months in all studies with continuing improvement up to 24 months (0.8 vs. 0.5 [p = 0.006], 1.3 vs. 0.6 [p < 0.001], 2.0 vs. 0.9 [p < 0.001] adjusted mean change from baseline [ml/sec] dutasteride vs. placebo groups for 1,3 and 24 months respectively). Dutasteride statistically significantly improved BPH-specific health status at 6 months in the pooled analysis [-0.63 vs. -0.41 adjusted mean score change from baseline for dutasteride vs. placebo groups (p = 0.003)], with sustained significant improvement up to the end of the study (24 months) [-1.0 vs. -0.26, adjusted mean score change from baseline for dutasteride vs. placebo groups (p < 0.001)]. The reduction from baseline in PV was significant from 1 month (-8.6 vs. - 2.9 adjusted mean % for dutasteride vs. placebo groups [p < 0.001]) and sustained PV reduction was seen up by to 2 years ( -28.5 % vs. -1.8% in the placebo group). There was a 57% reduction in the risk of AUR and 48% reduction of risk of BPH-related surgery compared with placebo over 2 years. A low withdrawal rate due to adverse events was reported (9% for either group) with withdrawals due to drug-related adverse events only slightly higher in the placebo group (4% vs. 3% for the dutasteride and placebo groups, respectively).

CONCLUSIONS: Dutasteride impacts all the key hallmarks of BPH: lower urinary tract symptoms, Qmax, BII, PV, risk of AUR and the need for BPH-related surgery. The drug was well tolerated with minimal drug-related adverse events. These findings highlight dutasteride as a potential therapy of choice for BPH management.










공지

☞ 성의 있는 글 하나가 큰 힘이 됩니다. 무성의 게시글,댓글은 신고바랍니다.
☞ 본 게시판에서 모발이식 수술 후기는 신고 바랍니다. (삭제 및 탈퇴)

댓글

  • 최신순
  • 추천순
    글목록

    모발이식 포토&후기

    1 16

    우리동네 모발이식 병원지도

    병원지도
    PC버전 로그인 개인정보처리방침 이용약관
    28년간 쌓아온 압도적 득모 노하우
    대한민국 대표 탈모 커뮤니티
    대표이사 : 서정교 | 사업자번호 : 324-87-02598
    대다모 구글플레이 다운로드 대다모 앱스토어 다운로드
    카카오톡 카카오톡으로 시작
    탈모사이트 1위 대다모 이메일로 시작하기 이메일로 시작
    닥터노비드
    탈모톡톡
    모발이식
    헤어라인/두피문신
    먹는 탈모약
    헤어&두피케어
    탈모 후기
    전문가상담
    탈모병원
    탈모콘텐츠
    대다모 댄디 바로가기 대다모 댄디 바로가기
    실시간 비대면 견적받기 비대면